L’ESSENTIEL
- An injectable solution can reprogram patients’ immune cells to fight cancer.
- The therapy eliminated some tumors in mice within weeks.
- Further clinical trials are needed before the new treatment becomes available.
A promising new technique offers a potential breakthrough in cancer treatment. A study published March 23, 2026, in Nature details a therapy that reprograms a patient’s own immune cells to combat the disease after a single injection. “I think this is just the beginning of a major wave of new therapies that will be truly revolutionary and save many lives,” said Justin Eyquem, the study’s lead author, in a statement. “I am extremely excited to be a part of it.”
An Injection to Reprogram a Patient’s Immune Cells
Researchers drew inspiration from existing CAR-T cell therapy, currently used to treat certain blood cancers. That process involves removing immune cells from a patient, genetically modifying them in a lab to target cancer, and then re-infusing them back into the patient.
While effective, CAR-T therapy is expensive and can be difficult for patients. Scientists sought a simpler approach, and they’ve achieved a similar result with an injectable solution that reprograms immune cells directly within the patient’s body.
No Trace of Leukemia in as Little as Two Weeks
After developing the solution, researchers tested it on mice with humanized immune systems, and diagnosed with aggressive leukemia, multiple myeloma, and a solid tumor. The results were striking: a single injection eliminated detectable leukemia in nearly all of the mice within two weeks. The treatment similarly showed significant effectiveness against multiple myeloma and the solid tumor, and potentially even surpassed the efficacy of traditional CAR-T therapy, which often struggles against solid tumors. Notably, the immune cells generated within the mice appeared to be more effective than those produced in a laboratory setting.
“What’s particularly remarkable is that the cells we generate in vivo actually seem better than those we produce in the lab,” explained Justin Eyquem. “We believe that when cells are taken from the body and grown in the laboratory, they lose some of their ability to differentiate into stem cells and proliferate, which is not the case here.”
Before this new treatment can turn into widely available, further clinical trials are necessary to confirm its safety and effectiveness in humans. The next steps involve verifying the therapy’s efficacy and safety, particularly in human patients.“If we can translate this approach to humans, we could significantly reduce costs, eliminate waiting times, and potentially allow local hospitals – and not just major cancer centers – to offer these life-saving therapies,” concluded Justin Eyquem. “This would truly democratize access to CAR-T cell therapy.”
Learn about Unicancer’s clinical trials
Search for cancer clinical trials in Canada
